文摘
The rBMD method has improved the accuracy and reproducibility of telavancin MIC testing. The objective of this study was to analyze the S. aureus isolates recovered from complicated skin and skin-structure infections patients treated using the rBMD method and evaluate the impact of the revised MICs on the clinical cure and microbiological eradication rates. Telavancin MIC values obtained by the rBMD were up to 8-fold lower than the values obtained by the original BMD method and all isolates remained susceptible to telavancin at the 0.12 μg/mL breakpoint. The clinical cure and microbiological eradication rates were comparable for patients with S. aureus, methicillin-resistant S. aureus, and S. aureus isolates with elevated vancomycin MICs (≥1 μg/mL). With the revision of the BMD method, telavancin MICs more accurately represent telavancin's in vitro potency against S. aureus.